Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jul;64(1):23–28. doi: 10.1038/bjc.1991.233

The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.

B Wängberg 1, O Nilsson 1, E Theodorsson 1, A Dahlström 1, H Ahlman 1
PMCID: PMC1977317  PMID: 1713051

Abstract

The use of a somatostatin analogue (SMS 201-995) has greatly facilitated the treatment of patients with the midgut carcinoid syndrome. Clinical studies have shown that SMS reduces the peripheral levels of tumour-produced serotonin (5-HT) and tachykinins, e.g. neuropeptide K (NPK), basally and after pentagastrin provocation. Some studies have indicated an inhibitory effect of SMS on tumour cell growth as well. In the present study we have investigated the effects of SMS on four different human midgut carcinoid tumours maintained in long term culture. Media levels of 5-HT and NPK-LI in tumour cell cultures decreased rapidly during incubation with SMS (10(-8)-10(-10) M) in all four tumours studied without evidence for tachyphylaxis (up to 6 weeks observation period). SMS treatment (10(-8) M) during 4 days reduced the media concentrations of 5-HT by 56%, while the intracellular contents of 5-HT were decreased by 27% indicating dual inhibitory effects on synthesis and secretion of 5-HT from tumour cells. The DNA contents of cultures were not affected by SMS (10(-8) M or 10(-10) M) treatment for 4 or 14 days. When tumour cell cultures were challenged with isoprenaline (IP) (10(-6) M) no reduction of the IP induced release of 5-HT could be detected after pretreatment of tumour cell cultures with SMS (10(-8) M) for 1 h, 4 h or 4 days. These studies provide evidence for a direct action of the somatostatin analogue on midgut carcinoid tumour cells, reducing both synthesis and secretion of hormones from tumour cells. This effect appears not to be related to inhibition of tumour cell growth. The inhibition of 5-HT secretion from tumour cells by SMS seems to operate via a second messenger system different from the one mediating the beta-adrenoceptor stimulated release of 5-HT.

Full text

PDF
23

Images in this article

24Figure 1
on p.24

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlman H., Ahlund L., Dahlström A., Martner J., Stenqvist O., Tylén U. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization. Anesth Analg. 1988 Dec;67(12):1142–1148. [PubMed] [Google Scholar]
  2. Ahlman H., Ahlund L., Nilsson O., Skolnik G., Theodorsson E., Dahlström A. Carcinoid tumour cells in long-term culture: release of serotonin but not of tachykinins on stimulation with adrenoceptor agonists. Int J Cancer. 1988 Oct 15;42(4):506–510. doi: 10.1002/ijc.2910420407. [DOI] [PubMed] [Google Scholar]
  3. Ahlund L., Nilsson O., Kling-Petersen T., Wigander A., Theodorsson E., Dahlström A., Ahlman H. Serotonin-producing carcinoid tumour cells in long-term culture. Studies on serotonin release and morphological features. Acta Oncol. 1989;28(3):341–346. doi: 10.3109/02841868909111204. [DOI] [PubMed] [Google Scholar]
  4. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T. J., Pless SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982 Sep 13;31(11):1133–1140. doi: 10.1016/0024-3205(82)90087-x. [DOI] [PubMed] [Google Scholar]
  5. Brodin E., Lindefors N., Dalsgaard C. J., Theodorsson-Norheim E., Rosell S. Tachykinin multiplicity in rat central nervous system as studied using antisera raised against substance P and neurokinin A. Regul Pept. 1986 Feb;13(3-4):253–272. doi: 10.1016/0167-0115(86)90044-3. [DOI] [PubMed] [Google Scholar]
  6. Cai R. Z., Szoke B., Lu R., Fu D., Redding T. W., Schally A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1896–1900. doi: 10.1073/pnas.83.6.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gorden P., Comi R. J., Maton P. N., Go V. L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35–50. doi: 10.7326/0003-4819-110-1-35. [DOI] [PubMed] [Google Scholar]
  8. Grönstad K. O., Nilsson O., Dahlström A., Skolnik G., Ahlman H. Adrenergic control of serotonin release from carcinoid tumor cells in vitro and in vivo. J Surg Res. 1987 Feb;42(2):141–146. doi: 10.1016/0022-4804(87)90111-9. [DOI] [PubMed] [Google Scholar]
  9. Kvols L. K., Martin J. K., Marsh H. M., Moertel C. G. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med. 1985 Nov 7;313(19):1229–1230. doi: 10.1056/NEJM198511073131915. [DOI] [PubMed] [Google Scholar]
  10. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663–666. doi: 10.1056/NEJM198609113151102. [DOI] [PubMed] [Google Scholar]
  11. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980 Mar 1;102(2):344–352. doi: 10.1016/0003-2697(80)90165-7. [DOI] [PubMed] [Google Scholar]
  12. Lamberts S. W., Hofland L. J., van Koetsveld P. M., Reubi J. C., Bruining H. A., Bakker W. H., Krenning E. P. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab. 1990 Sep;71(3):566–574. doi: 10.1210/jcem-71-3-566. [DOI] [PubMed] [Google Scholar]
  13. Lamberts S. W., Koper J. W., Reubi J. C. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest. 1987 Aug;17(4):281–287. doi: 10.1111/j.1365-2362.1987.tb02188.x. [DOI] [PubMed] [Google Scholar]
  14. Lamberts S. W., Reubi J. C., Uiterlinden P., Zuiderwijk J., van den Werff P., van Hal P. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinology. 1986 Jun;118(6):2188–2194. doi: 10.1210/endo-118-6-2188. [DOI] [PubMed] [Google Scholar]
  15. Lamberts S. W., Verleun T., Zuiderwijk J. M., Oosterom R. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion. Acta Endocrinol (Copenh) 1987 Jun;115(2):196–202. doi: 10.1530/acta.0.1150196. [DOI] [PubMed] [Google Scholar]
  16. Mascardo R. N., Sherline P. Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology. 1982 Oct;111(4):1394–1396. doi: 10.1210/endo-111-4-1394. [DOI] [PubMed] [Google Scholar]
  17. Nilsson O., Grönstad K. O., Goldstein M., Skolnik G., Dahlström A., Ahlman H. Adrenergic control of serotonin release from a midgut carcinoid tumour. Int J Cancer. 1985 Sep 15;36(3):307–312. [PubMed] [Google Scholar]
  18. Norheim I., Wilander E., Oberg K., Theodorsson-Norheim E., Lundqvist M. L., Lindgren P., Bergh J. Tachykinin production by carcinoid tumours in culture. Eur J Cancer Clin Oncol. 1987 Jun;23(6):689–695. doi: 10.1016/0277-5379(87)90264-1. [DOI] [PubMed] [Google Scholar]
  19. Oberg K., Norheim I., Theodorsson E., Ahlman H., Lundqvist G., Wide L. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab. 1989 Apr;68(4):796–800. doi: 10.1210/jcem-68-4-796. [DOI] [PubMed] [Google Scholar]
  20. Ponzio F., Jonsson G. A rapid and simple method for the determination of picogram levels of serotonin in brain tissue using liquid chromatography with electrochemical detection. J Neurochem. 1979 Jan;32(1):129–132. doi: 10.1111/j.1471-4159.1979.tb04519.x. [DOI] [PubMed] [Google Scholar]
  21. Redding T. W., Schally A. V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A. 1984 Jan;81(1):248–252. doi: 10.1073/pnas.81.1.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983 Dec 22;309(25):1556–1563. doi: 10.1056/NEJM198312223092506. [DOI] [PubMed] [Google Scholar]
  23. Reubi J. C. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) 1985 May;109(1):108–114. doi: 10.1530/acta.0.1090108. [DOI] [PubMed] [Google Scholar]
  24. Reubi J. C., Häcki W. H., Lamberts S. W. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab. 1987 Dec;65(6):1127–1134. doi: 10.1210/jcem-65-6-1127. [DOI] [PubMed] [Google Scholar]
  25. Reubi J. C., Maurer R., von Werder K., Torhorst J., Klijn J. G., Lamberts S. W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987 Jan 15;47(2):551–558. [PubMed] [Google Scholar]
  26. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]
  27. Souquet J. C., Sassolas G., Forichon J., Champetier P., Partensky C., Chayvialle J. A. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer. 1987 May 1;59(9):1654–1660. doi: 10.1002/1097-0142(19870501)59:9<1654::aid-cncr2820590922>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES